Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin

NCT04204837 is registered in ClinicalTrials.gov with Salzburger Landeskliniken as lead sponsor.

NCT NCT04204837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04204837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin
Lead sponsor
Salzburger Landeskliniken
Phase
Phase 2
Overall status
Recruiting
Start date
March 6, 2017
Completion date
December 31, 2027
Enrollment
61 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the skin